Celularity Inc. (CELU)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 14 | 21 | 18 | 23 | 54 | 27 | 27 | 44 |
| Operating profit | $m | -61 | -61 | ||||||
| Net profit | $m | -208 | -100 | 14 | -196 | -58 | -92 | -92 | -70 |
| EPS reported | $ | -3.59 | -3.69 | ||||||
| Operating cashflow per share | $ | -0.52 | -0.52 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | -0.52 | -0.52 | ||||||
| Free cash flow | $m | -13 | -13 | ||||||
| Net debt | $m | 8 | -24 | ||||||
| Book value equity | $m | -38 | -38 | ||||||
| Book value per share | $ | -1.49 | -1.49 | ||||||
| Number of shares | m | 25.6 | 25.6 | ||||||
| DPS (TTM paid) | $ | 0.23 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | -0.75 | -0.75 | ||||||
| P/S LTM | x | 1.07 | 1.07 | ||||||
| P/FCF LTM | x | -2.14 | -2.14 | ||||||
| EV/EBITDA LTM | x | -0.81 | -0.81 | ||||||
| EV/Sales LTM | x | 2.38 | 3.14 | ||||||
| Earnings Yield LTM | % | -3.23% | -2.13% | ||||||
| FCF Yield | % | -46.65% | -46.65% | ||||||
| Quality | |||||||||
| ROE | % | +241.19% | +411.46% | ||||||
| ROIC | % | -1.51% | -1.51% | ||||||
| Operating margin | % | -2.31% | -2.31% | ||||||
| Gross margin | % | +76.04% | +76.04% | ||||||
| FCF/Sales | % | -49.92% | -49.92% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -51.03% | -51.03% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | +20.76% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | -6.42% | 0.00% | ||||||
| FCF/Debt | x | -0.32 | -0.32 | ||||||
| Net Debt/EBITDA | x | -0.45 | -0.45 | ||||||
| EBIT/Net interest | x | -9.08 | -9.08 | ||||||
| Net debt/market cap | % | +49.28% | +28.80% | ||||||
| Net debt/Equity | x | -0.21 | 0.63 | ||||||
| Gross debt/equity | x | -1.07 | -1.07 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Celularity Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering "off-the-shelf" allogeneic cell therapies, which are developed from placental sources. These innovative treatments are designed to combat a range of serious conditions, including various cancers, immune system dysfunctions, and infectious diseases. The company’s operations are segmented into three distinct areas: Cell Therapy, Degenerative Disease, and BioBanking. Their therapeutic pipeline features several key candidates: CYCART-19, a placental-derived CAR-T therapy, currently in Phase I trials for B-cell malignancies; CYNK-001, an unmodified natural killer (NK) cell also from placental sources, advancing through Phase I trials for acute myeloid leukemia and Phase I/IIa trials for glioblastoma multiforme and COVID-19; and CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I for HER2+ gastric and gastroesophageal cancers. Furthermore, two mesenchymal-like adherent stromal cell candidates, APPL-001 and PDA-002 (both derived from placentas), are in pre-clinical development for Crohn's disease and facioscapulohumeral muscular dystrophy, respectively. In addition to its therapeutic development, Celularity is involved in commercial activities, offering surgical and wound care products like Biovance and Interfyl through sales and licensing agreements. The company also specializes in collecting stem cells from umbilical cords and placentas, providing storage services under its LifebankUSA brand. Founded in 2016, Celularity Inc. maintains its headquarters in Florham Park, New Jersey.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Celularity Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering "off-the-shelf" allogeneic cell therapies, which are developed from placental sources. These innovative treatments are designed to combat a range of serious conditions, including various cancers, immune system dysfunctions, and infectious diseases. The company’s operations are segmented into three distinct areas: Cell Therapy, Degenerative Disease, and BioBanking. Their therapeutic pipeline features several key candidates: CYCART-19, a placental-derived CAR-T therapy, currently in Phase I trials for B-cell malignancies; CYNK-001, an unmodified natural killer (NK) cell also from placental sources, advancing through Phase I trials for acute myeloid leukemia and Phase I/IIa trials for glioblastoma multiforme and COVID-19; and CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I for HER2+ gastric and gastroesophageal cancers. Furthermore, two mesenchymal-like adherent stromal cell candidates, APPL-001 and PDA-002 (both derived from placentas), are in pre-clinical development for Crohn's disease and facioscapulohumeral muscular dystrophy, respectively. In addition to its therapeutic development, Celularity is involved in commercial activities, offering surgical and wound care products like Biovance and Interfyl through sales and licensing agreements. The company also specializes in collecting stem cells from umbilical cords and placentas, providing storage services under its LifebankUSA brand. Founded in 2016, Celularity Inc. maintains its headquarters in Florham Park, New Jersey.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free